EFNB2 and breast carcinoma: Indeed, the potential utilization of Eph/ephrin signaling as prognostic indicators of disease progression or therapeutic targets, as in the correlation of EphB4/ephrin-B2 levels with the incidence of metastasis in breast cancer survivors [88], and the efficacy of targeting ephrin-B2 to limit tumor growth via attenuating adverse lymphangiogenesis and angiogenesis [89], are increasingly being recognized.